SWOG clinical trial number
S2433

Randomized Phase III Study of Second-Line Chemotherapy with or without Panitumumab for Locally Advanced or Metastatic KRAS Wild Type Pancreatic Adenocarcinoma

Open
Phase
Accrual
1%
Abbreviated Title
Randomized Phase III Study of Second-Line Chemotherapy with or without Panitumumab for Locally Advanced or Metastatic KRAS Wild Type Pancreatic Adenocarcinoma
Activated
12/26/2025
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS

Research committees

Gastrointestinal Cancer

Treatment

Panitumumab

Patient Study Materials

Patient Clinical Trial Summary
Download PDF of Patient Clinical Trial Summary

Other Study Materials

Publication Information Expand/Collapse

2026

S2433: Randomized Phase III Study of Second-Line Chemotherapy with or without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Safyan RA;Singh H;Guthrie KA;Sun V;Wadlow R;Gbolahan OB;Sohal D;Lowy AM;Ahmad S;Chiorean EG;Philip PA ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs TPS4264 TIP poster

Reports & Approvals

Trial Locations

Other Clinical Trials

SWOG Clinical Trial Number
S2433

Randomized Phase III Study of Second-Line Chemotherapy with or without Panitumumab for Locally Advanced or Metastatic KRAS Wild Type Pancreatic Adenocarcinoma
Research Committee(s)
Gastrointestinal Cancer
Activated
12/26/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
S2303

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Accrual
48%
Open
Phase
SWOG Clinical Trial Number
CTSU/A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
Phase